Brian Taylor Slingsby
Founder & Executive DirectorDr. Brian Taylor Slingsby, also known as BT, MD, PhD, MPH, also known as BT, serves as the Co-founder & Executive Chairman of Aculys Pharma LLC. He is Co-Founder of Crystalys Therapeutics and is its Board Observer since September 2026 and had been its Executive Chairman of the Board until September 2026. He serves as Director at Transposon Therapeutics, Inc. Dr. Brian is the Co-Founder, Executive Chairman and Chief Executive Officer of Kirilys Therapeutics, Inc. Dr. Slingsby is a Co-Founder & Executive Chairman at Pathalys Pharma Inc. Dr. Slingsby is Founder and Managing Director at Catalys Pacific. He is Founder & Executive Chairman of Mineralys Therapeutics, Inc. He is Director at Exalys Therapeutics, Inc. He is also the Founder, CEO and Executive Director of Global Health Innovative Technology (GHIT) Fund. He is a physician-scientist and biotechnology entrepreneur leading company creation efforts for the firm. Prior to Catalys Pacific, he founded the Global Health Innovative Technology (GHIT) Fund – the world’s first public-private fund focused on the development of new medicines for low- and middle-income countries. In his role as CEO and Executive Director at the GHIT Fund, he deployed investments and grew the fund in capital. In recognition of his contributions to global health, he has been awarded a Foreign Ministry Commendation from the Government of Japan. BT has authored peer-reviewed articles on medicine and public health and lectures at the Graduate School of Medicine at the University of Tokyo and Kyoto University. Dr. Slingsby graduated from Brown University with honors, earned his M.P.H. from Kyoto University and Ph.D. from the University of Tokyo and received his M.D. with honors from the George Washington University.
公司職務
- 公司名稱Mineralys Therapeutics, Inc.股票代碼MLYS職務Founder & Executive Director
